TSPAN32 and chronic myelogenous leukemia, BCR-ABL1 positive: This finding aligns with previously reported data in chronic myeloid leukemia (CML) [16] and our observations in Burkitt lymphoma [17], further supporting a potential tumor-suppressive role for TSPAN32 across distinct hematologic malignancies.